Acitretin: Could it be a new therapeutic player in the field of onychomycosis?

AbstractBackgroundOnychomycosis represents a therapeutic challenge. The complete cure rate with itraconazole pulse therapy remains unsatisfactory implying the need for an effective therapeutic regimen. Given the successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole, we investigated the therapeutic use of acitretin in onychomycosis.AimTo evaluate and compare the efficacy of combined itraconazole and acitretin versus monotherapy with each in onychomycosis.Patients and MethodsThe study included 135 adult patients with finger‐ and/or toenail onychomycosis. They were equally subdivided into 3 groups: itraconazole pulse therapy, acitretin and combined itraconazole/acitretin therapy. The drugs were administered for 3 months. Evaluation of severity was done by onychomycosis severity index score. Potassium hydroxide microscopy and culture were performed at baseline and at the end of the study.ResultsMycological and complete cure of onychomycosis was observed in 51.1% and 20% of the itraconazole group, 28.9% and 28.9% of the acitretin group, and 80% and 53.3% of the combined group. There was a statistically significant difference between groups in favour of the combined itraconazole/acitretin therapy (P ≤ .05).LimitationsSmall sample and short therapy duration.ConclusionsAcitretin could be a powerful therapeutic player in the field of onychomycosis, with greater efficacy when combined with itraconazole.